Multiple Myeloma | Unmet Need | US/EU | 2022
Multiple myeloma remains an incurable hematological malignancy despite the availability of numerous treatment options. Resistance to therapy is the primary challenge associated with the disease’s relapse and recurrence. The foremost goal in the third-line treatment of multiple myeloma is to extend patient survival. The mainstays of treatment combine multiple agents such as Bristol Myers Squibb’s Revlimid and Janssen’s Darzalex. Proteasome inhibitors such as Amgen / Ono Pharmaceutical’s Kyprolis and Takeda’s Ninlaro are also widely used. The emergence of Sanofi’s Sarclisa and Karyopharm’s Xpovio / Nexpovio has broadened the treatment options for high-risk patients in the third-line setting, but unmet need persists for more-effective therapies in this fragmented space.
QUESTIONS ANSWERED
- What treatment drivers and goals are most likely to influence the choice of third-line therapy in multiple myeloma?
- How do current therapies perform on key clinical drug attributes for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in this patient population?
- What trade-offs across clinical attributes and price are acceptable to surveyed hematologist-oncologists for a new therapy for third-line multiple myeloma?
PRODUCT DESCRIPTION
Unmet need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European hematologist-oncologists fielded in March 2022
Key companies: Janssen, Bristol Myers Squibb, Takeda, Amgen / Ono Pharmaceutical, Sanofi, Karyopharm Therapeutics
Key drugs: Darzalex, Revlimid, Ninlaro, Kyprolis, Pomalyst / Imnovid, Sarclisa, Xpovio / Nexpovio
